Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injections into the eye less frequently.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Retina Vitreous Associates of Florida
• Collaborator: Genentech, Inc.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Ability to provide written informed consent and comply with study assessments for the full duration of the study

• Age > 18 years

• Patient related considerations

• Phakic or pseudophakic patients with a known history of diabetes will be eligible.

• Women of reproductive age will be required to take a urine pregnancy test prior to administration of the study drug.

• Disease related considerations:

• Patients will have met standard, accepted diagnostic criteria for diabetes and will be currently treated with at least one systemic antihyperglycemic or insulin medication.

• Patients will have a BCVA ETDRS Snellen-equivalent less than or equal to 20/40

• Central foveal thickness on SD-OCT of >300um

Exclusion Criteria:

• Pregnancy (positive pregnancy test) or lactation Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.

• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated

• Participation in another simultaneous medical investigation or trial

• Foveal ischemia on IVFA

• Intraocular surgery less than 6 months ago

• Epiretinal membrane of clinical significance

• Prior vitrectomy

• Uncontrolled glaucoma

• Macular or peripheral laser within 90 Days from Day 0 injection

• Intravitreal steroid injection within 90 days from Day 0 injection

• Intravitreal or systemic anti-VEGF within 30 days from Day 0 injection